PTK2B and metastatic melanoma: To test this hypothesis, immunofluorescent labelling of activated Pyk2 was assessed in a panel of melanoma cells ranging from non-invasive in situ melanoma (WM1552 and WM1862) to invasive (WM115 and WM983A) and metastatic melanoma (WM983B and A375).